NCT05488314 2026-03-13
METalmark
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
Clinical Trials
6 trialsNCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05243641 2025-06-11
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02795429 2023-07-03
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Novartis
Phase 1/2 Completed
NCT02335944 2023-06-18
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Novartis
Phase 1/2 Terminated
NCT01870726 2018-05-30
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis
Phase 1/2 Terminated